Contributions of Laboratory Research to Current Understanding and Management of Leprosy

Shepard CC . Acid fast bacilli in nasal excretions in leprosy and results of inoculation of mice. Am J Hyg 1960; 71: 147–57.

Kircheimer WF Storrs EE . Attempts to establish the Armadillo (Dasypus novemcinctus Linn) as a model for the study of leprosy. 1. Report of lepromatoid leprosy in an experimentally infected armadillo. Int J Lepr 1971; 39: 693–702.

Clark-Curtiss JE Jacobs WR Docherty MA Molecular analysis of DNA and construction of genomic libraries of Mycobacterium leprae. J Bacteriol 1985; 161: 1093–102.

Satish M Essner RE Thole JER Clark-Curtiss JE . Identification and characterisation of antigenic determinants of Mycobacterium leprae that react with antibodies in sera of leprosy patients. Infect Immun 1990; 58: 1327–36.

Williams DL Gillis TP Portaels F. Geographically distinct isolates of Mycobacterium leprae exhibit no genotypic diversity by restriction fragment-length polymorphism analysis. Molecular Microbiology 1990; 4: 1653–9.

Eisenstein BI . The polymerase chain reaction. N Engl J Med 1990; 322: 178–83.

Hartskeerl RA De Wit MYL Klatser PR . Polymerase chain reaction for the detection of Mycobacterium leprae. J Gen Microbiol 1989; 135: 2357–64.

Grange JM . Mycobacteria and human disease. London: Edward Arnold, 1988.

Chakrabarty AK Maire MA Lamberr PH . SDS Page analysis of M. leprae protein antigens reacting with antibodies from sera from lepromatous patients and infected armadillos. Clin Exp Immunol 1982; 49: 523–31.

Engers HD Abe M Bloom BR Results of a World Health Organisation sponsored workshop on monoclonal antibodies to Mycobacterium leprae. Infect Immun 1985; 48: 603–605.

Watson JD . Leprosy: Understanding protective immunity. Immunol Today 1989; 10: 218–21.

Hartskeerl RA van Rens RM Stabel LFEM Selection and characterisation of recombinant clones that produce Mycobacterium leprae antigens recognised by antibodies in sera from household contacts of leprosy patients. Infect Immun 1990; 58: 281–2.

Young BD Lathigra R Hendrix R Stress proteins are immune targets in leprosy and tuberculosis. Proc Natl Acad Sci USA 1988; 85: 4267–70.

Shinnick TM Vodkin MH Williams JC . The Mycobacterium tuberculosis 65-kilodalton antigen is a heat shock protein which corresponds to common antigen and to the Escherichia coli GroEL protein. Infect Immun 1988; 56: 446–51.

Shinnick TM Sweetser D Thole J The etiologic agents of leprosy and tuberculosis share an immunoreactive protein antigen with the vaccine strain Mycobacterium bovis BCG. Infect Immun 1987; 55: 1932–5.

Gonzalez NM De Vries RRP HLA linked control of predisposition to lepromatous leprosy. J Infect Dis 1985; 151: 9–17.

Schurr E Morgan K Gros P Genetics of leprosy. Am J Trop Med Hyg 1991; 44(Suppl):4–11.

van Voorhis WC Kaplan G Sarno EN The cutaneous infiltrates of leprosy; cellular characterisation and the predominant T cell phenotype. N Engl J Med 1982; 307: 1593–7.

Mehra V Brennan PJ Rada E Lymphocyte suppression in leprosy induced by unique M. leprae glycolipid. Nature 1984; 308: 194–6.

Young DB . What's next in basic research? Int J Lepr 1991;59:95–101.

Bloom BR Godal T. Leprosy. Rev Infect Dis 1983; 5: 239–56.

Hastings RC Gillis TP Krahenbuhl JL Leprosy. Clin Micro Rev 1988; 1: 330–48.

Birdi TJ Antia NH . The macrophage in leprosy: A review on the current status. Int J Lepr 1989; 57: 511–25.

Young DB . Detection of mycobacterial lipids in skin biopsies from leprosy patients. Int J Lepr 1981; 49: 198–204.

Brett SJ Draper P Payne SN Rees RJW . Serological activity of a characteristic phenolic glycolipid from Mycobacterium leprae in sera from patients with leprosy and tuberculosis. Clin Exp Immunol 1983; 52: 271–9.

Cho S-N Yanagihara DI Hunter SW Serological specificity of phenolic glycolipid 1 from Mycobacterium leprae and use in serodiagnosis of leprosy. Infect Immun 1983; 41: 1077–83.

Cho S-N Hunter SW Gelber RH Rea TH Brennan PJ . Quantitation of the phenolic glycolipid of Mycobacterium leprae and relevance to glycolipid antigenemia in leprosy. J Infect Dis 1986; 153: 560–9.

Young DB Dissanayake S Miller RA Humans respond predominantly with IgM immunoglobulin to the species specific glycolipid of Mycobacterium leprae. J Infect Dis 1984; 149: 870–3.

Fine PEM Ponnighaus JM Burgess P Seroepidemiological studies of leprosy in northern Malawi based on an enzyme-linked immunosorbent assay using synthetic glycoconjugate antigen. Int J Lepr 1988; 56: 243–54.

Groenen G Pattyn SR Ghys P A longitudinal study of the incidence of leprosy in a hyperendemic area in Zaire, with special reference to PGL-antibody results. Int J Lepr 1990; 58: 641–50.

Ellard G. The chemotherapy of leprosy, part 1. Int J Lepr 1990; 58: 704–16.

WHO Technical Report Series, 675. (Chemotherapy of leprosy for control programmes: report of a WHO study group.) Geneva: World Health Organization, 1982.

Noordeen SK . A look at world leprosy. Lepr Rev 1991; 62: 72–86.

Petit JH Rees RJW . Sulphone resistance in leprosy. An experimental and clinical study. Lancet 1984; ii: 673–74.

Ji B-H. Drug resistance in leprosy — a review. Lepr Rev 1985; 56: 265–78.

Ellard GA . The Chemotherapy of leprosy. Part 2. Int J Lepr 1991; 59: 82–94.

Grosset J. Recent developments in the field of multidrug therapy and future research in chemotherapy. Lepr Rev 1986; 57(Suppl):223–34.

Hastings RC . Growth of Sulphone resistant M. leprae in the footpad of mice fed dapsone. Proc Soc Exp Bio Med 1977; 156: 544–5.

Levy L Shepard CC Fasal P. The bactericidal effect of rifampicin on M. leprae in man: (a) Single doses of 600, 900, and 1200 mg; (b) daily doses of 300 mg. Int J Lepr 1976; 44: 183–7.

Jacobson RR Hastings RC . Rifampicin resistant leprosy. Lancet 1976; ii: 1304–5.

Wheeler PR Ratledge C. Metabolism in Mycobacterium leprae, Mycobacterium tuberculosis and other pathogenic mycobacteria in tuberculosis and leprosy. Br Med Bull 1988; 44: 547–62.

Hall RM Ratledge C. Exochelin mediated iron acquisition by the leprosy bacillus. J Gen Microbiol 1987; 133: 193–9.

Grosset JH Ji B Guelpa-Lauras CC Perani EG N'Deli L. Clinical trial of Pefloxacin and ofloxain in the treatment of lepromatous leprosy. Int J Lepr 1990; 58: 281–95.

Franzblau SG Hastings RC . In vitro and in vivo activities of macrolides against Mycobacterium leprae. Antimicrob Agents Chemother 1988; 32: 1758–62.

Ji B Grosset JH . Recent advances in the chemotherapy of leprosy. Lepr Rev 1990; 61: 313–29.

Katoch VM Katoch K Bagga A. Immunotherapeutic trials using BCG and Mycobacterium strain w along with MDT in highly bacillated BL/LL cases. Oral Presentation VIth Santa Margherita Ligure meeting October 1990.

Kaplan G Sarno EN Job CK Cellular responses to the intradermal injection of recombinant human gamma interferon in lepromatous leprosy patients. Am J Pathol 1987; 128: 345–53.

Kaplan G Kiessling R Teklemariam S The reconstitution of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2. J Exp Med 1989; 169: 893–907.

Fine P Rodrigues L. Modern vaccines. Mycobacterial diseases. Lancet 1990; 335: 1016–19.

Editorial . Vaccines against leprosy. Lancet 1987; ii: 83.

Convit J Aranzazu N Pinardi ME Ulrich M. Immunological changes observed in indeterminate and lepromatous leprosy patients and Mitsuda — ve contacts after innoculation of a mixture of Mycobacterium leprae and BCG. Clin Exp Immunol 1979; 36: 214–20.

Convit J Ulrich M Aranzazu N Castellanos PL Pinardi ME Reyes O. The development of a vaccination model using two microorganisms and its application in leprosy and leshmaniasis. Lepr Rev 1986; 57: 263–73.

Fine P Ponnighaus JM . Background design and prospects of the Karonga Prevention Trial (KPT), a leprosy vaccine trial in northern Malawi. Trans R Soc Med Hyg (in press).

Chaturvedi RM Chirmule NB Yellapurkar MV Shaikh SV Deo MG . Effects of ICRC antileprosy vaccine in healthy subjects. Int J Lepr 1987; 55: 657–66.

Talwar GP . Vaccine based on Mycobacterium w. bacillus. Working paper presented at ‘vaccines’ workshop prior to XIII International Leprosy Congress, The Hague, The Netherlands, 1988.

Watson JD . Prospects for new generation vaccines for leprosy: Progress, barriers and future strategies. Int J Lepr 1989; 57: 834–43.

Singh NB Lowe Care Rees RJW Colston MJ . Vaccination of mice against M. leprae infection. Infect Immun 1989; 57: 653–5.

Gelber RH Brennan PJ Hunter SW Effective vaccination of mice against leprosy bacilli with subunits of Mycobacterium leprae. Infect Immun 1990; 58: 711–18.

Lamb FI Kingston AE Estrada-G I Colston MJ . Heterologous expression of the 65 kilo-dalton antigen of Mycobacterium leprae and murine T-cell responses to the gene product. Infect Immun 1988; 56: 653–55.

Stover CK de la Cruz VF Fuerst TR New use of BCG for recombinant vaccination. Nature 1991; 351: 456–60.

Aldovini A Young RA . Humoral and cell mediated immune responses to live recombinant BCG-HIV vaccines. Nature 1991; 351: 479–82.